Celecoxib does not affect osteointegration of cementless total hip stems.
Celecoxib's effect on prosthetic osteointegration in patients undergoing total hip arthroplasty was studied. In a prospective, placebo-controlled, double-blind study of 49 patients, 24 were randomized to celecoxib (200 mg/d) and 25 to placebo over 6 weeks. Bone markers, N-teleopeptide, and bone-specific alkaline phosphatase were obtained postoperatively, and at 6 and 12 weeks. No radiographic prosthetic subsidence occurred. There were no significant differences from baseline in periprosthetic bone mineral density between the celecoxib and placebo groups at 3 and 6 months. There were no significant differences in baseline BSAlkP values between the 2 groups. At 6 and 12 weeks, average BSAlkP values increased. Urinary NTx concentrations followed a skewed distribution. Normalized NTx concentrations were statistically significantly greater in the celecoxib group than the placebo group at 6 weeks but not at 12 weeks.